Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
About this item
Full title
Author / Creator
Margolin, Kim, Prof , Ernstoff, Marc S, MD , Hamid, Omid, MD , Lawrence, Donald, MD , McDermott, David, MD , Puzanov, Igor, MD , Wolchok, Jedd D, MD , Clark, Joseph I, Prof , Sznol, Mario, MD , Logan, Theodore F, MD , Richards, Jon, MD , Michener, Tracy, PharmD , Balogh, Agnes, MS , Heller, Kevin N, MD and Hodi, F Stephen, MD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Brain metastases commonly develop in patients with melanoma and are a frequent cause of death of patients with this disease. Ipilimumab improves survival in patients with advanced melanoma. We aimed to investigate the safety and activity of this drug specifically in patients with brain metastases. Methods Between July 31, 2008, a...
Alternative Titles
Full title
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1011199439
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1011199439
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(12)70090-6
